Avacta, a UK-based biotechnology company, has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets.
08 Mar 2017
Avacta Group - Initiation of Coverage
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Avacta Group - Initiation of Coverage
Avacta Group PLC (AVCT:LON) | 45.5 0.5 2.2% | Mkt Cap: 163.4m
- Published:
08 Mar 2017 -
Author:
Dr. Riccardo Lowi -
Pages:
8
Avacta, a UK-based biotechnology company, has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets.